Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a specific type of blood cancer called AML (Acute Myeloid Leukaemia) that involves particular genetic changes known as MECOM rearrangements or atypical 3q26 rearrangements (confirm with trial site for exact details on what this means for a specific case)
- People aged 18 or older
- People who have signed a written consent form agreeing to take part, in line with international and local research guidelines
Who may not be able to join:
- No specific exclusion criteria have been listed for this trial
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Giovanni Roti, Department of Medicine and Surgery, University of Parma, Parma
Phone: 0670390528
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Identification of MECOM/EVI1 regulators or downstream effectors potentially druggable
Can't join this trial?
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.